Pipeline
The Kairos Pharma Portfolio of Innovative Therapeutics
Our pipeline is focused on addressing critical unmet medical needs in cancer care and beyond. By combining groundbreaking science with a strategic intellectual property portfolio, we are developing innovative therapies designed to improve patient outcomes. Each stage of our pipeline reflects our commitment to translating cutting-edge research into real-world treatments. We aim to bring new hope to patients facing the most challenging diseases with every advancement.
Our robust pipeline represents a vision for transforming care and delivering life-changing therapies.
Portfolio
of innovative drugs
Milestones
June 2013 – Spun-off from Cedars-Sinai Medical Center
June 2014 – Raised $525K from Founders / Pennsylvania Biotechnology Grant
July 2016 – Name changed to Kairos Pharma, and licensed immunotherapy technology from Cedars-Sinai Medical Center
November 2019 – Merged with AcTcell Biopharma
July 2021 – Merged with Enviro Therapeutics
Preclinical work for ENV105 Prostate Cancer Phase II, ENV105 Non-Small Cell Lung Cancer Phase I, KROS201 Glioblastoma Phase I
IND for KROS201 cleared for recurrent glioblastoma
KROS101 GITR agonist molecule and KROS102 antagonist GITR molecule Preclinical studies
IND approved for Phase II Prostate Cancer Trial and for Phase I Non-Small Cell Lung Cancer for ENV105
Phase I and II multi-center trials with ENV105 enrolling
Preclinical development of KROS101, 102, 301, and 401
Safety data from Phase II trial and Phase I trial
Interim data of Phase II prostate cancer trial
Efficacy data from Phase II trial and Phase I trial
5-year Horizon for ENV105 FDA Approval with a Maturing Pipeline of Broader Prospective Applications
Phase I trials for KROS101
Related links
Technologies
Explore our innovative technologies, advanced platforms, and groundbreaking solutions driving breakthroughs in cancer treatment and addressing critical unmet medical needs.
Intellectual Property
Discover our robust intellectual property portfolio, protecting groundbreaking innovations and ensuring the advancement of transformative therapies for cancer and beyond.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
Pipeline
The Kairos Pharma Portfolio of Innovative Therapeutics
Our pipeline is focused on addressing critical unmet medical needs in cancer care and beyond. By combining groundbreaking science with a strategic intellectual property portfolio, we are developing innovative therapies designed to improve patient outcomes. Each stage of our pipeline reflects our commitment to translating cutting-edge research into real-world treatments. We aim to bring new hope to patients facing the most challenging diseases with every advancement.
Our robust pipeline represents a vision for transforming care and delivering life-changing therapies.
Portfolio
of innovative drugs
Milestones
2013 - 2021
- June 2013 – Spun-off from Cedars-Sinai Medical Center
- June 2014 – Raised $525K from Founders / Pennsylvania Biotechnology Grant
- July 2016 – Name changed to Kairos Pharma, and licensed immunotherapy technology from Cedars-Sinai Medical Center
- November 2019 – Merged with AcTcell Biopharma
- July 2021 – Merged with Enviro Therapeutics
2022
- Preclinical work for ENV105 Prostate Cancer Phase II, ENV105 Non-Small Cell Lung Cancer Phase I, KROS201 Glioblastoma Phase I
- IND for KROS201 cleared for recurrent glioblastoma
2023
- KROS101 GITR agonist molecule and KROS102 antagonist GITR molecule Preclinical studies
- IND approved for Phase II Prostate Cancer Trial and for Phase I Non-Small Cell Lung Cancer for ENV105
2024
- Phase I and II multi-center trials with ENV105 enrolling
- Preclinical development of KROS101, 102, 301, and 401
2025+
- Safety data from Phase II trial and Phase I trial
- Interim data of Phase II prostate cancer trial
- Efficacy data from Phase II trial and Phase I trial
- 5-year Horizon for ENV105 FDA Approval with a Maturing Pipeline of Broader Prospective Applications
- Phase I trials for KROS101
Related links
Technologies
Explore our innovative technologies, advanced platforms, and groundbreaking solutions driving breakthroughs in cancer treatment and addressing critical unmet medical needs.
Intellectual Property
Discover our robust intellectual property portfolio, protecting groundbreaking innovations and ensuring the advancement of transformative therapies for cancer and beyond.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
Pipeline
Portfolio
of innovative drugs
Milestones
2013 - 2021
June 2013 – Spun-off from Cedars-Sinai Medical Center
June 2014 – Raised $525K from Founders / Pennsylvania Biotechnology Grant
July 2016 – Name changed to Kairos Pharma, and licensed immunotherapy technology from Cedars-Sinai Medical Center
November 2019 – Merged with AcTcell Biopharma
July 2021 – Merged with Enviro Therapeutics
2022
- Preclinical work for ENV105 Prostate Cancer Phase II, ENV105 Non-Small Cell Lung Cancer Phase I, KROS201 Glioblastoma Phase I
- IND for KROS201 cleared for recurrent glioblastoma
2023
- KROS101 GITR agonist molecule and KROS102 antagonist GITR molecule Preclinical studies
- IND approved for Phase II Prostate Cancer Trial and for Phase I Non-Small Cell Lung Cancer for ENV105
2024
- Phase I and II multi-center trials with ENV105 enrolling
- Preclinical development of KROS101, 102, 301, and 401
2025+
- Safety data from Phase II trial and Phase I trial
- Interim data of Phase II prostate cancer trial
- Efficacy data from Phase II trial and Phase I trial
- 5-year Horizon for ENV105 FDA Approval with a Maturing Pipeline of Broader Prospective Applications
- Phase I trials for KROS101
Related links
Technologies
Intellectual Property
Discover our robust intellectual property portfolio, protecting groundbreaking innovations and ensuring the advancement of transformative therapies for cancer and beyond.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
